NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Moleculin Biotech, Inc. (MBRX) Stock Analysis

Moleculin Biotech, Inc. (MBRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MBRX

$6.31

+$6.03 (+2,153.57%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MBRX with… →

MBRX Key Statistics

As of Oct 21, 2026
Trading
Open
$6.00
Previous Close
$0.28
Day's Range
6.00–6.58
52-Week Range
3.22–315.00
Volume
41.72K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.00
Valuation
Market Cap
$6.43M
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$33.56M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.02M
1-Year Return
−47.53%
Dividend and dates
Avg Volume
68.42K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MBRX closed at $6.31, −47.53% over 1 year.

Moleculin Biotech, Inc. (MBRX) has a market capitalization of $6.43M.

In fiscal 2025, MBRX reported revenue of $0.00.

MBRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+90.63%
2025−92.21%
2024−86.79%
2023−19.06%
2022−43.01%
2021−61.10%
2020−12.90%
2019−12.02%
2018−44.09%
2017−18.42%
2016 (partial year)−65.02%

As of October 21, 2026.

MBRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$33.56M—
2024$0.00−$26.05M—
2023$0.00−$29.77M—
2022$0.00−$29.03M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$25.10M−$33.56M—
2024$0.00—−$26.64M−$26.05M—
2023$0.00—−$29.63M−$29.77M—
2022$0.00—−$30.64M−$29.03M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Moleculin Biotech, Inc. (MBRX) at $6.43M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 17.

MBRX last closed at $6.31 on October 21, 2026. That is +$6.03 (+2,153.57%) against the previous close. Over the past 52 weeks the price has ranged from $3.22 to $315.00. The latest close sits 95.96% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $33.56M.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

Beta against the wider market is reported at 2. Daily returns over the trailing 10 years annualize to a volatility of 696.78%. The trailing one-year total return is −47.53%. Across 10 years the annualized return works out at −51.02%.

Growth & Income

The record shows no dividend for MBRX.

2026 is still running; the total return is +90.63% year to date. Across the complete calendar years on file, 2019 returned −12.02% and 2025 returned −92.21%. Of the 9 complete calendar years on file, 0 finished higher.

Peer Comparison

Moleculin Biotech, Inc. (MBRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Moleculin Biotech, Inc. MBRX $6.43M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Visit website →